The inherited primary arrhythmia syndromes (IPAS) are a heterogeneous group of diseases caused by mutations in genes encoding for cardiac ion channels. People affected by one of these inherited diseases have no overt structural cardiac abnormalities but are at higher risk of sudden cardiac death due to the occurrence of life-threatening ventricular arrhythmias. Since the diagnostic ECG ventricular pattern of many IPAS is dynamic and often concealed, it is particularly difficult to estimate the prevalence of these diseases in the general population. However, most studies indicate that BrS is probably the most common with a prevalence ranging from 1:2,000 in Europe to 1:1,000 in Asian and south-east Pacific countries, followed by LQTS which has an estimated prevalence of four in 10,000 worldwide. 1 BrS may present overlapping ECG and clinical features with ERS and an ER pattern in the infero-lateral leads with a J-point elevation ≥0.2 mV has been observed in up to 6% of community-based middle-aged subjects without BrS. 3 SQTS and CPVT are the two rarest cardiac channelopathies with a prevalence of 2.7 in 100,000 and 1 in 10,000, respectively, worldwide. Paroxysmal AF is by far the most common atrial arrhythmia observed in these patients, and is occasionally the first and only manifestation of an inherited cardiac ion channel dysfunction.
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The vast majority of IPAS present with a specific ECG phenotype, characterised by an abnormal ventricular depolarisation and/or repolarisation phase, such as the coved-type ST-segment elevation in the right precordial leads, infero-lateral early repolarisation (ER), long QT and short QT intervals. 1, 2 These abnormalities reflect altered imbalance in ionic currents of cardiac myocytes, that may lead to development of ventricular arrhythmias such as monomorphic, polymorphic ventricular tachycardia (VT) or VF.
Since the diagnostic ECG ventricular pattern of many IPAS is dynamic and often concealed, it is particularly difficult to estimate the prevalence of these diseases in the general population. However, most studies indicate that BrS is probably the most common with a prevalence ranging from 1:2,000 in Europe to 1:1,000 in Asian and south-east Pacific countries, followed by LQTS which has an estimated prevalence of four in 10,000 worldwide. 1 BrS may present overlapping ECG and clinical features with ERS and an ER pattern in the infero-lateral leads with a J-point elevation ≥0.2 mV has been observed in up to 6% of community-based middle-aged subjects without BrS. 3 SQTS and CPVT are the two rarest cardiac channelopathies with a prevalence of 2.7 in 100,000 and 1 in 10,000, respectively, worldwide. 1 Both atrial and ventricular cardiomyocytes may express proteins encoded by the same mutated gene, which makes atrial arrhythmias common in patients with inherited primary arrhythmia syndromes. 4 Paroxysmal AF is by far the most common atrial arrhythmia observed in these patients, and is occasionally the first and only manifestation of an inherited cardiac ion channel dysfunction. 2, 5 While the prevalence of paroxysmal AF in the young (aged <50 years) is 0.1%, prevalence of AF is significantly higher among people with IPAS, ranging from 2% for patients with genetically proven LQTS to 30% for subjects with SQTS ( Table 1) . [6] [7] [8] In recent years, scientific evidence has been provided on the genetic basis of AF in the general population. Many monogenic mutations or rare variants have been identified. 14 
Long QT Syndrome
Eleven LQTS susceptibility genes have been described so far. However, mutations in three genes (KCNQ1-mediated LQT1, KCNH2-mediated LQT2, and SCN5A-mediated LQT3) account for 75% of clinically definite LQTS. It has been shown that a patient with LQTS has a 17-fold higher risk of experiencing AF before the age of 50 compared with populationbased individuals (RR 17.5, CI 2.2-139.6). 7 Of patients with genetically proven LQTS and AF, 63% present with a loss-of-function mutation in KCNQ1. 7 Kirchhoff et al. reported that patients with LQTS have altered atrial electrophysiology due to the prolongation of the atrial action potential and the atrial effective refractory period ( Figure 1 ). These alterations, possibly determined by a dysfunction of KCNQ1-encoded I Ks , lead to an enhanced susceptibility for an atrial form of torsades de pointes, having a longer cycle length, but resembling AF on the surface ECG ( Table 2) . 9 Similarly, Satoh and Zipes reported the effects of caesium chloride, a potassium channel blocker, in determining polymorphic atrial tachyarrhythmias by producing early after-depolarisations in canines. Based on these observations, it might be speculated that patients with LQTS present a similar arrhytmogenic platform for the development of both ventricular and atrial tachyarrhythmias.
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Short QT Syndrome
Three gain-of-function gene mutations encoding for cardiac potassium channels have been associated with SQTS: KCNH2 (SQT1), KCNQ1
(SQT2) and KCNJ2 (SQT3). AF is common in patients with SQTS and in half of all cases it is the first clinical manifestation of the syndrome. 8 The potential physio-pathological mechanism responsible in SQTS for both atrial and ventricular arrhythmias is shortening of the refractory period due to a gain of function of potassium channels.
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Early Repolarisation Syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia
No specific information is available on atrial arrhythmias in patients with ERS and CPVT. Junttila et al. reported that paroxysmal AF occurs in 15% of middle-aged subjects with an infero-lateral ER pattern. 12 A gain-of-function in gene encoding in the cardiac potassium channel (Kir6.1) is associated with both increased AF susceptibility and ER, indicating a role for the ion channel function in both ventricular and atrial repolarisation. 13 Ventricular pathophysiological mechanisms leading to ERS are still controversial and no specific studies have been carried out to assess the atrial electrophysiological abnormalities in these patients.
Atrial tachyarrhythmias seem to be rare in patients with CPVT.
Exercise-induced supraventricular arrhythmias have been only sporadically reported in patients with CPVT and no further specific data have been reported. 1, 4 More than half of CPVT cases are caused by autosomal-dominant missense mutations in the ryanodine receptor (RyR2), which is the major calcium (Ca 2+ ) release channel on the sarcoplasmic reticulum (SR) required for excitationcontraction coupling in cardiac muscle. 15 In mouse models of CPVT, it has been shown that RyR2-mediated diastolic SR Ca 2+ leak in atrial myocytes is associated with AF. 16 Moreover, most experimental studies agree that RyR2 phosphorylation by protein kinase A and Ca 2+ calmodulin-dependent protein kinase II can potentiate SR Ca 2+ leak, which is associated with ectopic activity and susceptibility to arrhythmias in CPVT.
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Atrial Arrhythmias in Brugada Syndrome
The ECG hallmark of BrS is the presence of a coved-type ST-segment elevation of >2 mm (Brugada type 1 ECG) in at least one right precordial lead (V1 and V2), placed in a standard or superior position. The ECG phenotypic expression of BrS is determined by the presence of an outward shift of the balance in repolarising currents Inherited Primary Arrhythmia Syndromes Pulmonary vein ectopic activity has been established to be the main trigger of paroxysmal AF in patients without structural heart disease. 31 Conversely, the pathophysiological mechanisms of AF in patients with BrS are still unknown and the role of PV triggering remains uncertain. 32 Moreover, long-term results of AF ablation in patients with BrS are relatively poor when compared with similarly aged with lone AF. 33 In fact, at a mean follow-up time of 22 months, nearly 65% of BrS patients were free from AF recurrences after having PV isolation.
The arrhythmogenic substrate of BrS might not be restricted to the ventricular level. Similar atrial changes could be the substrate for reentrant atrial tachyarrhythmias but have not been extensively studied.
The presence of a prominent transient outward current in atria and the observation that episodes of AF are triggered by closely coupled atrial extrasystoles points to the possibility that a substrate similar to that responsible for ventricular arrhythmogenesis may also be responsible for the development of AF in patients with BrS. 34 As for ventricular arrhythmias, the onset of AF in these patients is often preceded by fluctuations in autonomic tone and most AF episodes occur at night. 29 Vagal stimulation might reduce atrial conduction velocities and shorten the effective refractory period facilitating the induction of AF. 29, 30 Apart from AF, BrS can coexist with other forms of atrial arrhythmias, including atrioventricular nodal reentrant tachycardia (AVNRT).
Indeed, a concealed BrS ECG is present in 27% of patients presenting with AVNRT. 35 In these cases, genetic variants known or suspected to cause loss of function of sodium channel current may provide a mechanistic link between AVNRT and BrS and predispose to the expression of both phenotypes.
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Assessment of Atrial Electrical Activity in Patients with Brugada Syndrome
The baseline ECG of people who are prone to AF is easily obtainable and non-invasive and might reflect subclinical structural atrial abnormalities resulting from adverse remodelling of the atrial electroanatomical substrate. 36, 37 The P-wave on surface ECG represents atrial depolarisation and its duration may be a reliable non-invasive measurement of atrial conduction time. Previous studies have indicated that abnormal P-wave axis and long P-wave duration are strongly associated with an increased risk of AF. 38, 39 Moreover, P-wave indices which include a summary measure of duration, area and amplitude have been proposed to quantify the atrial electrical properties derived from the ECG, but they have shown only limited value in predicting AF occurrence. 40 The baseline ECG of patients with BrS reflects atrial electrical abnormalities resulting from the presence of an atrial channelopathy independently from the presence of previous episodes of AF. Patients with BrS have a longer P-wave duration compared with healthy controls. 41, 42 This anomaly might be due to the prolonged atrial action potential and increased intra-atrial conduction time reported by Kusano et al. 25 These researchers did not find any significant difference in electrophysiological parameters, such as intra-atrial conduction 
Conclusion and Future Perspectives
Available scientific data highlights the evidence that the Clinical Arrhythmias mechanisms underlying the development of atrial arrhythmias in these patients. In the last decade, particular attention has been focused on the development of atrial-selective drugs for the prevention of AF with the goal of avoiding ventricular pro-arrhythmic effects. 45, 46 While atrial-selective sodium channel blockers with preferential atrial activity, such as ranolazine, might be useful in the management of AF in the general population, different effects of these drugs might be revealed in patients with a cardiac channelopathy. Indeed, the use of atrial selective sodium channel blockers may be pro-arrhythmic in BrS patients and may, eventually, lead to the development of AF.
In-depth characterisation of pathogenesis of atrial arrhythmias in IPAS might have significant clinical implications in the diagnostic and therapeutic management of a much larger group of individuals at risk of AF and, in general, in a very large group of patients affected by lone atrial fibrillation or other cardiac causes.
Clinical Perspective
• The arrhythmogenic substrate of an inherited ion channel dysfunction is not restricted to the ventricular level and similar abnormalities affect the atrial electrophysiological properties creating the substrate for the occurrence of atrial tachyarrhythmias.
• Patients with Brugada syndrome present with a concealed abnormal atrial phenotype that can be detected even in the absence of an overt ventricular phenotype.
• In-depth characterisation of pathogenesis of atrial arrhythmias in patients with cardiac channelopathies have significant clinical implications in the diagnostic and therapeutic management and lead to a better understanding of the pathophysiological mechanisms and to a more appropriate individualised treatment.
